A Polygenic Risk Score for Predicting Racial and Genetic Susceptibility to Prurigo Nodularis

Increased cardiovascular risks and mortality in prurigo nodularis: a global cohort study

“…As PN was shown in other studies 9 , 10 , 11 to be more frequent in Black and African American individuals, we conducted an ethnicity-specific analysis to identify RD between ethnic backgrounds. To this end, sub-groups with control patients or patients with PN with skin of colour (n = 13,612 for both groups after propensity matching) and white control patients or patients with PN (n = 42,553) were identified.…”

“… 5 , 6 , 7 , 8 Overall prevalence is estimated at 72 per 100,000 individuals with a female predominance and higher frequencies in Black and African American individuals. 9 , 10 , 11 PN is associated with a variety of systemic disorders, including chronic kidney and cardiovascular diseases, HIV, chronic hepatitis C infection, chronic obstructive pulmonary disease, but also chronic inflammatory skin diseases like atopic dermatitis, psychiatric comorbidities and neoplasms. 11 , 12 , 13 , 14 , 15 , 16…”

Comprehensive plasma cytokine and chemokine profiling in prurigo nodularis reveals endotypes in Type 2 inflammation

“…Additionally, there is a need for studies focused on the efficacy of dupilumab in patients of African American or Black race. This is warranted given the findings of decreased response in this patient population in our retrospective analysis, the disproportionate prevalence and morbidity of PN among African Americans 15 , 54 , and phase 3 clinical trials for dupilumab included only 5% (8/160) African American patients, and were enriched for Caucasian and Asian PN patients 19 . Observation of only African American, Asian, and Caucasian patients limits broad generalizations, particularly about other races.…”

“…Heterogeneity is also evident in the clinical presentation, systemic comorbidity burden, and treatment response of PN patients 14 . In particular, African American patients demonstrate a genetic predisposition towards development of PN, bear a heavier comorbidity burden, and often exhibit more fibrotic and hyperkeratotic nodules compared to other racial groups 11 , 15 – 17 . Additionally, there is evidence of heterogeneity in response to immunomodulatory treatments, with some patient subgroups responding better to neural or immunomodulatory targeted therapies 18 .…”

Clinical utility of peripheral blood laboratory testing in the diagnostic workup of prurigo nodularis: A multicenter cohort study

“… 6 Since African Americans are disproportionately affected by PN, and African American patients with PN tend to have faster progression of chronic renal disease and higher comorbidity burden compared to their Caucasian counterparts, screening for renal disease may be particularly useful in this patient population. 6 , 34 , 35 …”